Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

BACKGROUND Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement...

A. Zemánková, B. Melichar, Michal Eid et al. · 0 citations
Aug 2026

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

BACKGROUND Enfortumab vedotin (EV) has transformed treatment for advanced urothelial carcinoma (aUC), but outcomes vary. Machine learning (ML) with explainable artificial intelligence (XAI) may improve survival prediction. METHODS Data from 544 aUC patients receiving EV after platinum chemotherapy and immunotherapy (...

K. Sridharan, O. Fiala, G. Sivaramakrishnan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.